

HHCS Human Hepatocytes Cryopreserved for Suspension assays
Cell Specification – Certificate of Analysis (CoA)

Lot HH160531-3

Batch Release: November 11, 2022

Donor data

Species: Human	Gender: female Size: 156 cm Non-Smoker	Age: 68 years Weight: 58 kg
Serology: HAV, HBV, HCV, HIV 1/2: negative	Diagnosis: metastasis of colorectal cancer	
Medical History: chemotherapy (Folfox, 12 cycles until 06/2015)	Therapy: atypical resection Medication: L-Thyroxin 100 mg Telmisartan 60 mg	

Cryopreservation and Thawing

Cryopreservation:	Thawing: n=3
Date: May 31, 2016	Post-thaw viability: 90.0 ± 6.1 %
Amount per vial: 10.4 x 10 ⁶ cells	Post-thaw yield per vial: 5.4 ± 0.9 x 10 ⁶ cells
	Recovery: 52 %

Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10⁶ cells in 0.5 ml HPM-Cryo):

Time (h)	0	0.5	1	1.5	2	3	4
Viability (%)	83.9	86.9	81.7	75.9	75.0	63.0	33.3

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: M. Reu

Verified by: K. Damrau